Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2022-12-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于在上海市设立全资子公司进展情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the establishment of a wholly-owned subsidiary by the company. It details the board meeting approval, registration completion, and business license information. There is no financial data, no report attached or referenced as published, and no mention of voting results or management changes beyond the subsidiary setup. This fits the category of a general regulatory announcement about corporate structure changes but not a board or management change announcement per se. Therefore, it is best classified as a Regulatory Filing (RNS). The document length is short and it is an announcement, not a full report or detailed financial disclosure.
2022-12-12 Chinese
关于控股股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of shares involved, pledge start and end dates, and the pledgee. This type of disclosure is related to changes in share ownership or shareholding status but specifically concerns the pledge of shares by a major shareholder. It is not a financial report, earnings release, or management discussion. It is also not a voting result or AGM material. The document fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related shareholding events such as pledges by controlling shareholders. The document length is short and focused on this specific share pledge event, confirming it is not a full report or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2022-12-09 Chinese
关于创新药HSK31858片II期临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of the first patient enrollment in a Phase II clinical trial for a new drug (HSK31858). It includes details about the drug, the clinical trial phase, regulatory approvals, and risk warnings. The document is short (1144 characters) and serves as an update on clinical trial progress rather than a financial report or detailed regulatory filing. It does not contain financial data, audit information, management changes, or voting results. It is an announcement of a clinical development milestone, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2022-12-06 Chinese
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and the pledgee. There is no financial performance data, no discussion of financial results, no meeting materials, no voting results, and no mention of any report publication. The content is a regulatory disclosure about share pledging, which fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about share pledge status by a major shareholder. The document length is short (1534 characters), and it is not an announcement of a report publication but a direct disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-30 Chinese
关于控股股东部分股份质押及解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by a controlling shareholder of the company. It details the number of shares pledged, the dates, the pledgees, and the cumulative pledge status. There is no financial performance data, no management discussion, no earnings information, no legal proceedings, no merger or acquisition details, and no meeting or voting results. The document is a regulatory announcement about share pledges by insiders, which fits the category of Major Shareholding Notification (MRQ) as it involves significant share ownership changes and disclosures related to share pledges by a major shareholder.
2022-11-28 Chinese
关于控股股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder's total pledged shares, and related information. There is no financial report, earnings data, or management discussion. The document is a specific announcement about share pledge status, which fits the category of Transaction in Own Shares (POS), as it relates to changes in the company's own shares held by insiders or controlling shareholders.
2022-11-21 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.